UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Myriad Genetics (NASDAQ: MYGN) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's President and CEO Paul J. Diaz, along with COO Sam Raha, will deliver a presentation on Wednesday, January 15, at 3:45 PM PT (6:45 PM ET).
Investors and interested parties can access the presentation through a live webcast available in the investor relations section of Myriad's website at investor.myriad.com. An archived version of the presentation will be made available following the live event.
Myriad Genetics (NASDAQ: MYGN) ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare che si terrà a San Francisco. Il presidente e CEO dell'azienda, Paul J. Diaz, insieme al COO Sam Raha, presenteranno un intervento mercoledì 15 gennaio, alle 15:45 PT (18:45 ET).
Investitori e parti interessate possono accedere alla presentazione attraverso un webcast in diretta disponibile nella sezione relazioni con gli investitori del sito web di Myriad all'indirizzo investor.myriad.com. Una versione archiviata della presentazione sarà resa disponibile dopo l'evento dal vivo.
Myriad Genetics (NASDAQ: MYGN) ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare en San Francisco. El presidente y CEO de la compañía, Paul J. Diaz, junto con el COO Sam Raha, dará una presentación el miércoles 15 de enero, a las 3:45 PM PT (6:45 PM ET).
Los inversores y partes interesadas pueden acceder a la presentación a través de un webcast en vivo disponible en la sección de relaciones con inversores del sitio web de Myriad en investor.myriad.com. Una versión archivada de la presentación estará disponible después del evento en vivo.
Myriad Genetics (NASDAQ: MYGN)는 샌프란시스코에서 열리는 제43회 J.P. Morgan Healthcare 회의에 참여할 예정이라고 발표했습니다. 회사의 대통령이자 CEO인 Paul J. Diaz와 COO인 Sam Raha가 1월 15일 수요일, 오후 3:45 PT (오후 6:45 ET)에 발표를 할 것입니다.
투자자와 관심 있는 쪽은 Myriad 웹사이트의 투자자 관계 섹션에서 제공되는 실시간 웹캐스트를 통해 발표에 접근할 수 있습니다. 실시간 이벤트 후 발표의 아카이브 버전이 제공될 예정입니다.
Myriad Genetics (NASDAQ: MYGN) a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare qui se déroulera à San Francisco. Le président et CEO de l'entreprise, Paul J. Diaz, ainsi que le COO Sam Raha, présenteront une communication mercredi 15 janvier à 15h45 PT (18h45 ET).
Les investisseurs et les parties intéressées peuvent accéder à la présentation via un webinaire en direct disponible dans la section des relations avec les investisseurs du site web de Myriad à l'adresse investor.myriad.com. Une version archivée de la présentation sera disponible après l'événement en direct.
Myriad Genetics (NASDAQ: MYGN) hat die Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Konferenz in San Francisco angekündigt. Der Präsident und CEO des Unternehmens, Paul J. Diaz, sowie COO Sam Raha werden eine Präsentation am Mittwoch, den 15. Januar, um 15:45 Uhr PT (18:45 Uhr ET) halten.
Investoren und Interessierte können die Präsentation über einen Live-Webcast abrufen, der im Bereich Investor Relations auf der Website von Myriad unter investor.myriad.com verfügbar ist. Eine archivierte Version der Präsentation wird nach der Live-Veranstaltung zur Verfügung gestellt.
- None.
- None.
News release updated to include the members of the management team speaking at the conference.
SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET).
The presentation will be available through a live webcast in the investor relations section of Myriad’s website at investor.myriad.com. An archived edition of the presentation will be available later that day.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
FAQ
When is Myriad Genetics (MYGN) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Myriad Genetics' (MYGN) J.P. Morgan Healthcare Conference presentation?
Who will represent Myriad Genetics (MYGN) at the 2025 J.P. Morgan Healthcare Conference?
Where is the 2025 J.P. Morgan Healthcare Conference being held for MYGN's presentation?
